These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 2045206)

  • 1. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
    Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Holden SA; Herman TS; Epelbaum R; Pardee AB; Dezube B
    Anticancer Res; 1991; 11(4):1555-60. PubMed ID: 1746913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of etanidazole with cyclophosphamide and platinum complexes.
    Teicher BA; Herman TS; Shulman L; Bubley G; Coleman CN; Frei E
    Cancer Chemother Pharmacol; 1991; 28(3):153-8. PubMed ID: 1830248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fluosol-DA/carbogen on etoposide/alkylating agent antitumor activity.
    Teicher BA; Bernal SD; Holden SA; Cathcart KN
    Cancer Chemother Pharmacol; 1988; 21(4):281-5. PubMed ID: 3131032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
    Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
    Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
    Schwartz GN; Teicher BA; Eder JP; Korbut T; Holden SA; Ara G; Herman TS
    Cancer Chemother Pharmacol; 1993; 32(6):455-62. PubMed ID: 8258194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new concentrated perfluorochemical emulsion and carbogen breathing as an adjuvant to treatment with antitumor alkylating agents.
    Teicher BA; Holden SA; Ara G; Ha CS; Herman TS; Northey D
    J Cancer Res Clin Oncol; 1992; 118(7):509-14. PubMed ID: 1624542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
    Siemann DW; Beyers KL
    Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma.
    Teicher BA; Holden SA; al-Achi A; Herman TS
    Cancer Res; 1990 Jun; 50(11):3339-44. PubMed ID: 2334928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP; Teicher BA; Holden SA; Cathcart KN; Schnipper LE; Frei E
    Cancer Res; 1989 Feb; 49(3):595-8. PubMed ID: 2910481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
    Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
    Ning SC; Hahn GM
    Cancer Res; 1991 Nov; 51(21):5910-4. PubMed ID: 1718588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA; Holden SA; Ara G; Northey D
    Anticancer Res; 1993; 13(6A):2101-6. PubMed ID: 7507654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAI: effects on cytotoxic therapies in vitro and in vivo.
    Teicher BA; Holden SA; Chen YN; Ara G; Korbut TT; Northey D
    Cancer Chemother Pharmacol; 1994; 34(6):515-21. PubMed ID: 7923563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.